Bavaria grows by 8% and bills 87 million, supported by its consolidation in Europe

» class=»RichTextAlignLeft» src=»https://empresaexterior.com/upload/images/05_2026/7298_clinica-baviera.png» />

 

The ophthalmology company Baviera The company has announced its results for the first quarter of fiscal year 2026, achieving total revenues of €87 million. This 8% increase compared to the same period last year reinforces its operational and expansion strategy in key European markets.

 

Global financial evolution and operational growth

 

 

 

During the first three months of this year, the net profit reported by Baviera It reached 14,7 million euros, registering a robust increase of 14% compared to the 2025 figures. Likewise, the group's operating profit (EBITDA) at the international level climbed to 26,4 million euros, demonstrating the high profitability of the business model.

 

 

 

As of March 31, the company's ophthalmological infrastructure comprises a total of 154 operational clinics strategically deployed across the European continent, consolidating its network of specialized medical assistance.

 

 

 

Financial Indicator (Q1 2026)	Amount Reached	Year-on-year change
Consolidated Revenue	87 millones de euros	+ 8 %
Operating Profit (EBITDA)	26,4 millones de euros
Net profit	14,7 millones de euros	+ 14 %
Global Volume of Clinics	154 medical centers

 

 

 

 

Strategic breakdown by international markets

 

 

 

The financial performance of Baviera It shows particular dynamics in each of the countries where it operates, driving the group's revenue in a coordinated manner:

 

 

 

• España: It has consolidated its position as the leading market with 91 clinics and a turnover of €58,6 million. EBITDA reached €21 million (10% higher than the previous year). This growth is driven by the increase in laser and intraocular lens surgeries, thanks in part to recent openings during 2025 and early 2026.
• Alemania y Austria: Operating commercially under the brand CARE VisioThe group has 34 clinics, including key operations in VienaThis territory has generated €16,7 million in revenue. Its EBITDA, at €4,9 million, has registered a technical decrease of 6% due to a higher proportion of intraocular surgeries, new hires for the medical team, and a significant increase in marketing resources.
• Italia: With 10 facilities, the Mediterranean country maintains an upward trajectory with revenues of €6,5 million and an EBITDA of €1,2 million. The excellent performance of this market is primarily due to the high volume of laser surgeries and the sustained optimization of its profitability.
• Reino Unido: Integrated in July 2024 under the brand umbrella OptimaxThe 19 British clinics have contributed €5,2 million to the corporation. Despite posting a negative EBITDA of €794.000, this figure represents a significant improvement of 36%, confirming that the integration process is proceeding according to the plans set by management.

 

 

 

Key points and frequently asked questions about the results of Baviera

 

 

 

What are the company's revenues and net profits for this period?

 

 

 

The corporation has achieved total revenues of €87 million, representing year-on-year growth of 8%. Furthermore, its net profit has surged by 14%, reaching €14,7 million in the first quarter of 2026.

 

 

Which market has performed the strongest and what are its key factors?

 

 

 

España It leads the way in revenue with 58,6 million euros, thanks to the positive evolution of ophthalmological surgeries (laser and intraocular) and the operational profitability of the recent openings undertaken in recent months.

 

 

How is the integration process evolving in the British market?

 

 

 

The market Reino Unido, operated through OptimaxIt is progressing according to the strategic roadmap. It has contributed €5,2 million in revenue and, although it maintains a negative operating result, this has been reduced by 36%, showing a firm improvement towards profitability.